Skip to main content

Excellence in research and development of non-coding RNA DIAGnostics in ONcology

Objective

Cancer occurs in more than 2 million individuals every year in Europe alone. It is widely recognized that early diagnosis and monitoring of the disease - during therapy and post-treatment follow-up- is a key step for successful patient management: it helps to offer on-time curative intervention and selecting the most appropriate therapy, improves the quality of life, while contributing to reduce the economic and social burden for both patients and society. There are screening programs available for early detection of some cancers such as colorectal cancer (CRC). Unfortunately, current CRC screening tests suffer with unsatisfactory sensitivity and specificity and low compliance of targeted population. On the other hand, there are cancers with poorly performing biomarkers as in the case of hepatocellular carcinoma (HCC), or no biomarkers at all (e.g. renal cell carcinoma (RCC), which limits not only the screening options but also the diagnosis or monitoring of the disease. Therefore, there is a need for new diagnostic biomarkers and accurate technologies to enable precise detection of asymptomatic tumors in a short time, low costs and, if possible, with minimal invasiveness and risks for the patients. From this perspective, cancer specific small non-coding RNAs (small ncRNAs) circulating in body fluids such as blood serum or plasma present promising diagnostic approach. Project RNADIAGON aims at development of personal skills and knowledge of early-stage and experienced researchers working in the field of small non-coding RNA diagnostics from five European research institutions through their long-term stays at one of the world-leading ncRNAs research centers in United States and traineeships at the education center and manufacturing facilities of industrial partner developing small ncRNAs-based certified diagnostics. This research and innovation staff exchange will increase the scientific excellence and quality of related research in the EU research institutions.

Coordinator

Masarykova univerzita
Net EU contribution
€ 165 600,00
Address
Zerotinovo Namesti 9
601 77 Brno
Czechia
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00

Participants (5)

BIOVENDOR - LABORATORNI MEDICINA AS
Czechia
Net EU contribution
€ 82 800,00
Address
Karasek 1767/1
621 00 Brno
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
MEDIZINISCHE UNIVERSITAT GRAZ
Austria
Net EU contribution
€ 96 600,00
Address
Auenbruggerplatz 2
8036 Graz
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
UNIVERSITATEA DE MEDICINA SI FARMACIE IULIU HATIEGANU CLUJ-NAPOCA
Romania
Net EU contribution
€ 124 200,00
Address
Victor Babes Street 8
400012 Cluj-napoca
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
UNIVERSITA DEGLI STUDI DI FERRARA
Italy
Net EU contribution
€ 96 600,00
Address
Via Ariosto 35
44121 Ferrara
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Germany
Net EU contribution
€ 96 600,00
Address
Martinistrasse 52
20251 Hamburg
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
Region
Baden-Württemberg Stuttgart Stuttgart, Stadtkreis

Partners (1)

Partner

Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.

THE UNIVERSITY OF TEXAS SYSTEM
United States
Net EU contribution
€ 0,00
Address
Colorado Street 601
78701 2982 Austin
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00